Active, not recruitingPhase 3NCT02962414
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Studying Tuberous sclerosis complex
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- everolimus(drug)
- Enrollment
- 206 enrolled
- Eligibility
- 2-65 years · All sexes
- Timeline
- 2017 – 2027
Study locations (19)
- TGen APNNA, Phoenix, Arizona, United States
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- UCSF Benioff Children s Hospital, Oakland, California, United States
- Rady Children s Hospital, San Diego, California, United States
- University of Colorado School of Medicine, Aurora, Colorado, United States
- Connecticut Childrens Medical Cntr, Hartford, Connecticut, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Minnesota Epilepsy Group, Saint Paul, Minnesota, United States
- Atlantic Health Systems, Morristown, New Jersey, United States
- Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States
- Oregon Health Sciences University, Portland, Oregon, United States
- Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Texas Scottish Rite Hos for Child, Dallas, Texas, United States
- Texas Childrens Hospital, Houston, Texas, United States
- Novartis Investigative Site, Sydney, New South Wales, Australia
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02962414 on ClinicalTrials.govOther trials for Tuberous sclerosis complex
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06879665TANDem-2: Closing the Gap to Interventions for TANDVrije Universiteit Brussel
- RECRUITINGPHASE3NCT07403266Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)Oils4Cure
- RECRUITINGNANCT06160310Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)David M. Ritter
- RECRUITINGPHASE2NCT05104983Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyDarcy Krueger
- RECRUITINGNANCT06764602Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous SclerosisIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGNANCT04198181The Effectiveness and Safety of Resective Epilepsy Surgery for TREBeijing Children's Hospital
- RECRUITINGNANCT00001465Study of the Disease Process of LymphangioleiomyomatosisNational Heart, Lung, and Blood Institute (NHLBI)